Indi Molecular, Inc.

California Institute of Technology

Regeneron Pharmaceuticals, Inc.

Heather Dawn Agnew

James R Heath

Bert Tsunyin Lai

Blake Farrow

Suresh Mark Pitram

Arundhati Nag

Rosemary Dyane Rohde

Anders Eliasen

Paul Edward Kearney

Samir Das

Steven Wesley Millward

David Bunck

Jingxin Liang

Tsun Yin Lai

Kenneth Charles Fang

Scott Law

The present application provides stable heterobiligands made up of peptide-based IDO1 ligands and small molecule inhibitors of IDO1 and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing IDO1 heterobiligands, capture agents, and imaging agents.

Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)

The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.

Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.

Compositions, delivery systems, and methods useful in tumor therapy

The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.

Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)

The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.

Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making

The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making

Disclosed are compounds, compositions, and methods involving theranostic capture agent for a target where the capture agent is (a) a precursor that can be loaded with a detectable moiety, a therapeutic moiety, or both, (b) loaded with a detectable moiety, (c) loaded with a therapeutic moiety, or (d) loaded with both a detectable moiety and a therapeutic moiety. Also disclosed are stable peptide-based PSMA capture agents and methods of use as detection agents.

Theranostic capture agents, compositions, and methods of using and making

The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

IL-17F-specific capture agents, compositions, and methods of using and making

The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.

VEGF-specific capture agents, compositions, and methods of using and making

Multi-ligand capture agents comprising two or more ligands are described, and related compositions, methods and systems.

Capture agents and related compositions, methods and systems

The present disclosure relates to capture agents for the detection and/or separation of one or more targets in a sample. Described herein are multi-ligand capture agents comprising two or more ligands, and related compositions, methods and systems. In certain embodiments, the capture agents disclosed herein can be used for performing assays, including but not limited to assays for the detection and/or separation of targets.

Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.

Growing community of inventors

Culver City, CA, United States of America

Heather Dawn Agnew